$KRYS
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
Krish S. Krishnan
CEO
275
Employees
$332.27
Current Price
$7.91B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 8 | $8,227,952.56 | 25,000 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 8 | $8,227,952.56 | 25,000 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 8 | $8,227,952.56 | 25,000 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 9 | $8,575,222.56 | 26,000 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 32 | $24,174,934.86 | 76,642 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | ROSSI DINO A Director | Sale | 4,896 | $330.36 | $1,617,422.00 | View Details |
| Aug 14, 2026 | ROSSI DINO A Director | Sale | 5,226 | $327.39 | $1,710,960.52 | View Details |
| Aug 14, 2026 | ROSSI DINO A Director | Sale | 40 | $333.23 | $13,329.20 | View Details |
| Aug 14, 2026 | ROSSI DINO A Director | Sale | 2,287 | $326.60 | $746,940.60 | View Details |
| Aug 14, 2026 | ROSSI DINO A Director | Sale | 3,095 | $331.43 | $1,025,786.06 | View Details |
| Aug 14, 2026 | ROSSI DINO A Director | Sale | 341 | $325.60 | $111,029.09 | View Details |
| Aug 14, 2026 | ROSSI DINO A Director | Sale | 1,687 | $328.52 | $554,205.14 | View Details |
| Aug 14, 2026 | ROSSI DINO A Director | Sale | 7,428 | $329.60 | $2,448,279.94 | View Details |
| Jun 25, 2026 | Thomas John Charles EVP, General Counsel | Sale | 1,000 | $347.27 | $347,270.00 | View Details |
| Jun 4, 2026 | Krishnan Suma Director | Sale | 480 | $305.87 | $146,815.20 | View Details |
| Jun 4, 2026 | Krishnan Suma Director | Sale | 1,348 | $307.09 | $413,963.79 | View Details |
| Jun 4, 2026 | Krishnan Suma Director | Sale | 320 | $300.75 | $96,240.00 | View Details |
| Jun 4, 2026 | Krishnan Suma Director | Sale | 400 | $304.89 | $121,957.56 | View Details |
| Jun 4, 2026 | Krishnan Suma Director | Sale | 3,803 | $308.89 | $1,174,707.91 | View Details |
| Jun 4, 2026 | Krishnan Suma Director | Sale | 247 | $303.17 | $74,883.06 | View Details |
| Jun 4, 2026 | Krishnan Suma Director | Sale | 2,801 | $309.95 | $868,156.23 | View Details |
| Jun 4, 2026 | Krishnan Suma Director | Sale | 593 | $302.25 | $179,234.72 | View Details |
| Jun 4, 2026 | Krishnan Suma Director | Sale | 2,039 | $310.94 | $634,000.54 | View Details |
| Jun 4, 2026 | Krishnan Suma Director | Sale | 240 | $311.65 | $74,796.00 | View Details |
| Jun 4, 2026 | Krishnan Suma Director | Sale | 12,729 | $307.81 | $3,918,070.21 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.